Tilray Brands, Inc. (TLRY) is strengthening its foothold in Europe’s largest medical cannabis market with the launch of three new EU-GMP certified strains under its Good Supply brand. The move comes as Tilray shares have soared more than 130% in August, fueled by investor optimism around potential U.S. cannabis policy shifts and ongoing international expansion.
The new offerings will roll out across Germany beginning in September and will be available in both 15 g jars for patients and 500 g packs for pharmacies. These additions build on Tilray Medical’s established reputation for consistent, pharmaceutical-grade cannabis supply across Europe.
Germany, which legalized medical cannabis in 2017, has emerged as a critical hub in Tilray’s global operations. With one of the largest patient populations and robust pharmacy distribution frameworks in Europe, the country represents a cornerstone of Tilray’s medical cannabis strategy.
Tilray already distributes its medical portfolio widely across Germany, leveraging its production and logistics infrastructure in both Portugal and Germany. The new strains expand the reach of Good Supply, one of Canada’s most recognized cannabis brands, adapted here for medical prescriptions under Germany’s regulated framework.
As regulatory momentum in the U.S. and abroad continues to reshape the cannabis industry, Tilray is positioning itself as a global leader with diversified offerings across medical, wellness, and consumer markets.
The post Tilray Brands Expands Medical Cannabis Portfolio in Germany appeared first on PRISM MarketView.
